OBJECTIVE: To assess the therapeutic effects of cannabis, cannabis-derived products and synthetic cannabinoids for rheumatoid arthritis. DESIGN: This is the protocol of a systematic review. DATA SOURCES: Searches will be conducted in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), trial registries, grey literature and in a centralized repository in L-OVE (Living OVerview of Evidence). L-OVE is a platform that maps PICO questions to evidence from Epistemonikos database. ELIGIBILITY CRITERIA FOR SELECTING STUDIES AND METHODS: We will include randomized controlled trials evaluating therapeutic use of cannabis, cannabis-derived products and synthetic cannabinoids for rheumatoid arthritis. Our primary interest will be in trials comparing the intervention with placebo or no treatment (intervention plus optimal treatment vs placebo plus optimal treatment or optimal treatment alone) in patients receiving optimal treatment for rheumatoid arthritis. Optimal treatment will be defined as disease modifying anti-rheumatic drugs. Two reviewers will independently screen each study for eligibility, extract data, and assess the risk of bias. We will perform random-effects meta-analyses and use Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of the evidence for each outcome. ETHICS AND DISSEMINATION: The Scientific Ethics Committee of the Pontificia Universidad Católica de Chile granted ethical exemption for the realization of this study. Results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media and will be sent to relevant international organizations discussing this topic.

中文翻译：

---

大麻，大麻衍生产品和合成大麻素在类风湿关节炎中的治疗用途：系统评价方案

目的：评估大麻，大麻衍生产品和合成大麻素对类风湿关节炎的治疗效果。设计：这是系统审查的协议。数据来源：检索将在PubMed / Medline，Embase，Cochrane对照试验中央登记册（CENTRAL），试验登记册，灰色文献以及L-OVE（证据的现存OVerview）集中存储中进行。L-OVE是一个平台，可将PICO问题映射到Epistemonikos数据库的证据。选择研究和方法的资格标准：我们将包括随机对照试验，评估大麻，大麻衍生产品和合成大麻素在类风湿性关节炎中的治疗用途。我们的主要兴趣是在比较接受类风湿性关节炎最佳治疗的患者中将干预与安慰剂或不治疗（干预加最佳治疗与安慰剂加最佳治疗或单独最佳治疗）进行比较的试验。最佳治疗将定义为抗风湿药。两名评审员将独立筛选每项研究的资格，提取数据并评估偏倚风险。我们将进行随机效果的荟萃分析，并使用建议评估，发展和评估等级（GRADE）来评估每种结果的证据确定性。道德与传播：智利天主教大学科学伦理委员会为实现这项研究提供了伦理豁免。